These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 29177699)

  • 21. Pharmacokinetics of duloxetine hydrochloride enteric-coated tablets in healthy Chinese volunteers: a randomized, open-label, single- and multiple-dose study.
    Zhao RK; Cheng G; Tang J; Song J; Peng WX
    Clin Ther; 2009 May; 31(5):1022-36. PubMed ID: 19539103
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety, Tolerability, and Pharmacokinetics of Treprostinil Palmitil Inhalation Powder for Pulmonary Hypertension: A Phase 1, Randomized, Double-Blind, Single- and Multiple-Dose Study.
    Ismat FA; Usansky HH; Villa R; Zou J; Teper A
    Adv Ther; 2022 Nov; 39(11):5144-5157. PubMed ID: 36070132
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tolerability and pharmacokinetics of ranolazine following single and multiple sustained-release doses in Chinese healthy adult volunteers: a randomized, open-label, Latin square design, phase I study.
    Tan QY; Li HD; Zhu RH; Zhang QZ; Zhang J; Peng WX
    Am J Cardiovasc Drugs; 2013 Feb; 13(1):17-25. PubMed ID: 23355361
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacokinetics of Single Doses of BI 425809 in Healthy Chinese and Japanese Subjects: A Randomized Study.
    Tsuda Y; Ugai H; Wunderlich G; Shin JG
    Clin Ther; 2019 May; 41(5):961-971. PubMed ID: 31005336
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety, tolerability, and pharmacokinetics of the novel pan-phosphodiesterase inhibitor ZSP1601 in healthy subjects: a double-blinded, placebo-controlled first-in-human single-dose and multiple-dose escalation and food effect study.
    Zhu X; Wu M; Wang H; Li H; Lin J; Peng Y; Hu Y; Li C; Ding Y
    Expert Opin Investig Drugs; 2021 May; 30(5):579-589. PubMed ID: 33682556
    [No Abstract]   [Full Text] [Related]  

  • 26. A phase I study of the safety, tolerability, and pharmacokinetics of contezolid acefosamil after intravenous and oral administration in healthy Chinese subjects.
    Yang H; Jin Y; Wang H; Yuan H; Wang J; Li S; Hu Y; Yang H; Li X; Liang H; Wu J; Cao G; Zhang J
    Antimicrob Agents Chemother; 2023 Nov; 67(11):e0079623. PubMed ID: 37902402
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation of the Efficacy of BI 425809 Pharmacotherapy in Patients with Schizophrenia Receiving Computerized Cognitive Training: Methodology for a Double-blind, Randomized, Parallel-group Trial.
    Harvey PD; Bowie CR; McDonald S; Podhorna J
    Clin Drug Investig; 2020 Apr; 40(4):377-385. PubMed ID: 32036587
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacokinetics, safety, and tolerability of GLPG0259, a mitogen-activated protein kinase-activated protein kinase 5 (MAPKAPK5) inhibitor, given as single and multiple doses to healthy male subjects.
    Namour F; Vanhoutte FP; Beetens J; Blockhuys S; De Weer M; Wigerinck P
    Drugs R D; 2012 Sep; 12(3):141-63. PubMed ID: 22950522
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Novel CRTH2 Antagonist BI 1021958 at Single Oral Doses in Healthy Men and Multiple Oral Doses in Men and Women With Well-Controlled Asthma.
    Fowler A; Koenen R; Hilbert J; Blatchford J; Kappeler D; Benediktus E; Wood C; Gupta A
    J Clin Pharmacol; 2017 Nov; 57(11):1444-1453. PubMed ID: 28609567
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety, tolerability, pharmacokinetics, and food effect of baicalein tablets in healthy Chinese subjects: A single-center, randomized, double-blind, placebo-controlled, single-dose phase I study.
    Dong R; Li L; Gao H; Lou K; Luo H; Hao S; Yuan J; Liu Z
    J Ethnopharmacol; 2021 Jun; 274():114052. PubMed ID: 33753147
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical Pharmacokinetics and Safety of ALZ-801, a Novel Prodrug of Tramiprosate in Development for the Treatment of Alzheimer's Disease.
    Hey JA; Yu JY; Versavel M; Abushakra S; Kocis P; Power A; Kaplan PL; Amedio J; Tolar M
    Clin Pharmacokinet; 2018 Mar; 57(3):315-333. PubMed ID: 29063518
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacokinetics, Safety and Tolerability of Once-Weekly Subcutaneous Semaglutide in Healthy Chinese Subjects: A Double-Blind, Phase 1, Randomized Controlled Trial.
    Shi A; Xie P; Nielsen LL; Skjøth TV; He X; Haugaard SP
    Adv Ther; 2021 Jan; 38(1):550-561. PubMed ID: 33159658
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Farnesoid X receptor agonist tropifexor attenuates cholestasis in a randomised trial in patients with primary biliary cholangitis.
    Schramm C; Wedemeyer H; Mason A; Hirschfield GM; Levy C; Kowdley KV; Milkiewicz P; Janczewska E; Malova ES; Sanni J; Koo P; Chen J; Choudhury S; Klickstein LB; Badman MK; Jones D
    JHEP Rep; 2022 Nov; 4(11):100544. PubMed ID: 36267872
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacokinetics, Safety and Tolerability of ABT-494, a Novel Selective JAK 1 Inhibitor, in Healthy Volunteers and Subjects with Rheumatoid Arthritis.
    Mohamed MF; Camp HS; Jiang P; Padley RJ; Asatryan A; Othman AA
    Clin Pharmacokinet; 2016 Dec; 55(12):1547-1558. PubMed ID: 27272171
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacokinetics, pharmacodynamics, and tolerability of the dipeptidyl peptidase IV inhibitor LC15-0444 in healthy Korean men: a dose-block-randomized, double-blind, placebo-controlled, ascending single-dose, Phase I study.
    Lim KS; Kim JR; Choi YJ; Shin KH; Kim KP; Hong JH; Cho JY; Shin HS; Yu KS; Shin SG; Kwon OH; Hwang DM; Kim JA; Jang IJ
    Clin Ther; 2008 Oct; 30(10):1817-30. PubMed ID: 19014837
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Multiple Rising Doses of Oral BI 425809, a GlyT1 Inhibitor, in Young and Elderly Healthy Volunteers: A Randomised, Double-Blind, Phase I Study Investigating Safety and Pharmacokinetics.
    Moschetti V; Schlecker C; Wind S; Goetz S; Schmitt H; Schultz A; Liesenfeld KH; Wunderlich G; Desch M
    Clin Drug Investig; 2018 Aug; 38(8):737-750. PubMed ID: 29846887
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacokinetics and tolerability of etamicastat following single and repeated administration in elderly versus young healthy male subjects: an open-label, single-center, parallel-group study.
    Nunes T; Rocha JF; Vaz-da-Silva M; Falcão A; Almeida L; Soares-da-Silva P
    Clin Ther; 2011 Jun; 33(6):776-91. PubMed ID: 21704242
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Safety, tolerability, pharmacokinetics, and immunogenicity of an anti-SARS-CoV-2 monoclonal antibody HFB30132A after single dose intravenous administration in healthy Chinese subjects: a phase 1, randomized, double-blind, placebo-controlled study.
    Li S; Wu X; Li N; Cao G; Wang J; Chen Y; Li S; He J; Wu J; Yang H; Lin K; Qiu C; Liu A; Zhou H; Adrian F; Schweizer L; Zhang W; Gu J; Zhang J
    Front Pharmacol; 2023; 14():1117293. PubMed ID: 37332355
    [No Abstract]   [Full Text] [Related]  

  • 39. Pharmacokinetics and tolerability of single and multiple doses of ticagrelor in healthy Chinese subjects: an open-label, sequential, two-cohort, single-centre study.
    Li H; Butler K; Yang L; Yang Z; Teng R
    Clin Drug Investig; 2012 Feb; 32(2):87-97. PubMed ID: 22168538
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacokinetics and Safety of the Tyrosine Kinase 2 Inhibitor Deucravacitinib in Healthy Chinese Subjects.
    Jing S; Lin Y; Dockens R; Marchisin D; He B; Girgis IG; Chimalakonda A; Murthy B; Aras U
    Dermatol Ther (Heidelb); 2023 Dec; 13(12):3153-3164. PubMed ID: 37981596
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.